| N | 5-Year DFS (%) (95 % CI) | HR (95 % CI) | p-valuea |
---|---|---|---|---|
Age | ||||
  < 35 | 30 | 82.6 [68.2–100] | 1 |  |
  ≥ 35 | 726 | 90.9 [88.5–93.4] | 0.5 [0.2–1.3] | 0.136 |
SBR Grade | ||||
 1–2 | 462 | 93.2 [90.5–95.9] | 1 |  |
 3 | 285 | 86 [81.4–91] | 1.8 [1.1–2.9] | 0.0138 |
Pathological tumor size | ||||
 pT1 | 391 | 91.2 [87.9–94.5] | 1 |  |
 pT2 | 320 | 90 [86.2–94] | 1.1 [0.7–1.8] |  |
 pT3-T4 | 36 | 88.2 [78–99.8] | 1.1 [0.4–3] | 0.9514 |
PVI | ||||
 No | 558 | 92.3 [89.7–95] | 1 |  |
 Yes | 178 | 85 [79–91.4] | 2.3 [1.4–3.7] | 0.0007 |
Hormone receptors | ||||
 Negative | 208 | 86.8 [81.6–92.4] | 1 |  |
 Positive | 526 | 92.5 [89.9–95.2] | 0.7 [0.4–1.1] | 0.1059 |
HER2 | ||||
 Negative | 507 | 91 [88–94.1] | 1 |  |
 Positive | 96 | 95.7 [91–100] | 0.6 [0.2–1.6] | 0.376 |
IHC subtypes | ||||
 Luminal A | 289 | 95.1 [92.1–98.2] | 1 |  |
 Luminal B/HER2-negative | 82 | 80.1 [69.8–92] | 4.3 [2–9.1] |  |
 Luminal B/HER2-positive | 58 | 100 [100–100] | 0.7 [0.2–3.3] |  |
 HER2 | 37 | 89 [77.6–100] | 1.8 [0.5–6.2] |  |
 Triple-negative | 127 | 87.6 [80.7–95] | 2.6 [1.2–5.5] | 0.0006 |